ERC Starting Grant · 2022
Intestinal fibrosis is a common and serious complication of inflammatory bowel disease (IBD). While intestinal inflammation can be treated pharmacologically based on our current understanding of the underlying pathogenesis, little is known about the mechanisms driving fibrogenesis. Thus no approved therapies exist for intestinal fibrosis. While stromal cells lie at the heart of fibrogenesis, our knowledge of how immune-derived signals instruct aberrant tissue repair and fibrosis is limited. We recently highlighted that the immune-stromal cell axis is a crucial component of IBD pathogenesis. Our research discovered that the IL-6 family cytokine oncostatin-M (OSM) plays a central role in…
From the public funding record at EU CORDIS. Describes the funded project, not the reviews below.